MetaStat (MTST) is a molecular diagnostic company that develops and commercializes driver-based diagnostic tests for the early and reliable prediction of cancer metastasis. MetaStat is focused on breast, lung, colorectal and prostate cancers where aggressive cancer is responsible for approximately 90% of all deaths.
MetaStat’s driver-based technology platform is built on the identification and understanding of the tumor microenvironment and the pivotal role of the Mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors. Both our MetaSite Breast™ and MenaCalc™ assays are designed to accurately stratify patients based on the aggressiveness of their tumor and risk the cancer will spread. MetaStat's testing platform improves treatment planning decisions by identifying patients at high-risk of metastasis who need aggressive therapy and by identifying patients at low-risk of metastasis who can be spared from the harmful side effects and expense of chemotherapy.
MetaStat’s head office and state-of-the-art CLIA-certified diagnostic laboratory are located in Boston, MA.